This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why You Should Add Cencora Stock to Your Portfolio Now
by Zacks Equity Research
COR continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
SYK Stock Down Despite Q4 Earnings Beat and Spine Biz Divestment Plans
by Zacks Equity Research
SYK's fourth-quarter results reflect strong segmental performance, along with a rise in operating margin.
CALID Arm Growth to Support Bruker Shares Amid Macro Issues
by Zacks Equity Research
BRKR's NANO Life Science fluorescence microscopy is gaining from product innovation and research demand.
IDXX Stock Set to Benefit From IDEXX Cancer Dx Diagnostic Panel Launch
by Zacks Equity Research
IDEXX launches new cancer Dx Panel with early detection test for canine lymphoma.
ISRG Stock Falls Despite Q4 Earnings Beat & Robust Procedures
by Zacks Equity Research
ISRG's fourth-quarter results reflect a healthy demand for procedures. Higher pricing boosts procedure sales. An improvement in margins buoys well.
Strategic Acquisitions to Support STERIS Stock Amid Macro Issues
by Zacks Equity Research
STE expects bioprocessing revenues to grow in the second half of fiscal 2025.
Reasons to Hold Avanos Medical Stock in Your Portfolio Now
by Zacks Equity Research
AVNS' strong product line and focus on R&D raise optimism about the stock.
Here's Why You Should Add Surmodics Stock to Your Portfolio Now
by Zacks Equity Research
SRDX stock falls more than 6% so far this year. However, this provides a unique opportunity to generate double-digit return within a couple of months.
Charles River Launches Apollo for CRADL to Boost Research, Stock Rises
by Zacks Equity Research
CRL introduces Apollo for CRADL, integrating the technology stack across its robust portfolio.
Completion of Whole Blood Assets Sale to GVS Likely to Boost HAE Stock
by Zacks Equity Research
Haemonetics completes the sale of whole blood assets to GVS, S.p.A.
Buy 4 Low-Beta Stocks AVO, TXO, PEN & STRA to Beat Market Volatility
by Nilanjan Banerjee
It is imperative to build a portfolio of low-beta stocks to navigate a volatile market. AVO, TXO, PEN & STRA are well-poised to gain.
Will CRL Stock Gain From Integration of Akron Bio's CSS Product Line?
by Zacks Equity Research
Charles River and Akron Bio collaborate to boost operations by integrating CGMP materials into the Cell Therapy Platform.
3 Reasons Why Growth Investors Shouldn't Overlook Penumbra (PEN)
by Zacks Equity Research
Penumbra (PEN) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Illumina Partners NVIDIA for Genomic Advancements, ILMN Stock Climbs
by Zacks Equity Research
ILMN teams up with NVIDIA to advance technology platforms for the analysis and interpretation of multiomic data.
Zacks.com featured highlights YPF Sociedad, Telefonica, Penumbra, Deckers Outdoor and Abercrombie & Fitch
by Zacks Equity Research
YPF Sociedad, Telefonica, Penumbra, Deckers Outdoor and Abercrombie & Fitch have been highlighted in this Screen of The Week article.
5 Must-Buy Efficient Stocks to Increase Your Portfolio Returns
by Santanu Roy
Invest in companies like YPF, TEF, PEN, DECK and ANF to make the most of higher efficiency levels.
AxoGen, Inc. (AXGN) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
AxoGen (AXGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
ILMN Stock Set to Gain From Latest Updates to the NovaSeq X Series
by Zacks Equity Research
Illumina advances NovaSeq X Series with a software upgrade and the new 25B 100-cycle and 200-cycle kits.
Penumbra (PEN) Surges 6.3%: Is This an Indication of Further Gains?
by Zacks Equity Research
Penumbra (PEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Reasons to Add Penumbra Stock to Your Portfolio Now
by Zacks Equity Research
PEN stays on investors' radars due to its strong Thrombectomy business and international growth plans.
IART or PEN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
IART vs. PEN: Which Stock Is the Better Value Option?
Reasons to Retain Phibro Stock in Your Portfolio Now
by Zacks Equity Research
PAHC's prospering Vaccine business sparks optimism for future growth. However, headwinds such as unfavorable foreign exchange might hamper the company's operations.
Reasons to Retain Medtronic Stock in Your Portfolio Now
by Zacks Equity Research
Investors continue to be optimistic about MDT due to its impressive Neuroscience portfolio. Yet, the dull macroeconomic scenario poses a concern to the company's margins.